热门资讯> 正文
摩根士丹利将传奇生物评级从增持下调至持平，维持51美元目标价
2022-01-06 23:50
10:49 AM EST, 01/06/2022 (MT Newswires) -- Legend Biotech (LEGN) has an average rating of outperform and price targets ranging from $51 to $71, according to analysts polled by Capital IQ.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: )
Price: 43.55, Change: -1.12, Percent Change: -2.51
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
